Haisco Pharmaceutical Group has entered a licensing and research collaboration with Eli Lilly to develop new medicines across various therapeutic areas. Under the agreement, Haisco will discover up to five innovative target programs, while Lilly will handle clinical development and commercialization. Haisco is set to receive up to $87 million in upfront payments and potentially $2.97 billion in milestones, along with royalties on future sales. This partnership marks a significant step in Haisco’s strategy to boost global expansion and innovation in the pharmaceutical sector.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.manilatimes.net/2026/06/01/tmt-newswire/pr-newswire/haisco-announces-licensing-and-research-collaboration-agreement-with-lilly-to-develop-innovative-medicines-across-multiple-therapeutic-areas/2355560
